Skip to main content

Table 1 Result of combination therapy strategy in hematologic malignancies

From: Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies

Combination therapy strategy Disease state(s) Efficacy Reference or Clinicaltrials.gov identifier Phase
Venetoclax + low-dose cytarabine Previously untreated AML ORR: 54%
Median OS: 10.1 months
Median DOR: 8.1 months
Wei et al.
NCT02287233
[17]
Ib/2
Venetoclax + HAMs (decitabine or azacitidine) Treatment-naïve AML ORR: 68% (99/145)
Median OS: 17.5 months
Median DOR: 11.3 months
MRD negative: 29% (28/97)
DiNardo et al.
NCT02203773
[16]
Ib
Venetoclax + ibrutinib Previously untreated high-risk and elderly CLL ORR: 88% (29/33)
Estimated 1-year PFS: 98%
Estimated 1-year OS: 99%
BM MRD negative: 61% (20/33)
Jain et al.
NCT02756897
[72]
II
Venetoclax + rituximab RR CLL ORR: 86% (42/49)
Estimated 2-year PFS: 82%
Estimated 2-year OS: 89%
BM MRD negative: 80% (20/25)
Seymour et al.
NCT01682616
[74]
I
Venetoclax + rituximab vs bendamustine + rituximab RR CLL ORR: 93.3% vs 67.7%
CR/CRi: 26.8% vs 8.2%
2-year PFS: 84.9% vs 36.3%
2-year OS: 91.9% vs 86.8%
BM MRD negative: 27.3% vs 1.5%
Seymour et al.
NCT02005471
[75]
III
Venetoclax + obinutuzumab Previously untreated and RR CLL RR and 1L patients
ORR: 95% (41/43) and 100% (32/32)
Estimated 24-month PFS: 85.4% and 90.6%
Median DOR: 40.9 months and NR (not reached)
BM MRD negative: 64% (26/42) and 78% (25/32)
Flinn et al.
NCT01685892
[79]
Ib
Venetoclax + ibrutinib + obinutuzumab RR CLL ORR: 92% (11/12)
Estimated 24-month PFS: 92%
BM and PB MRD negative: 50% (6/12)
Rogers et al.
NCT02427451
[76]
Ib
Venetoclax + R-CHOP/G-CHOP RR NHL (DLBCL, FL) ORR of all patients: 87.5%
CR/CRi of R-CHOP and G-CHOP: 79.2% and 78.1%
1-year PFS of R-CHOP and G-CHOP: 70% and 100%
Zelenetz et al.
NCT02055820
[93]
Ib
Venetoclax + bendamustine + rituximab RR NHL (DLBCL, FL, and MZL) ORR of all patients: 65%
Median DOR of all patients: 38.3 months
Median PFS of all patients: 10.7 months
Median OS of all patients: not reached
De Vos et al.
NCT01594229
[91]
Ib
Venetoclax + ibrutinib RR or previously untreated MCL ORR: 71% (17/24)
12-month estimated PFS: 75%
12-month estimated OS: 79%
BM MRD negative: 67% (16/24)
Tam et al.
NCT02471391
[102]
II
Venetoclax + bortezomib + dexamethasone RR MM ORR: 67% (44/66)
Median DOR: 9.7 months
Median TTP: 9.5 months
Moreau et al.
NCT01794507
[110]
Ib
  1. AML acute myeloid leukemia, BM bone marrow, CLL chronic lymphocytic leukemia, CR complete remission, CRi complete remission with incomplete count recovery, DLBCL diffuse large B-cell lymphoma, DOR duration of remission, FL follicular lymphoma, HMA hypomethylating agent, NHL non-Hodgkin's lymphoma, MCL mantle cell lymphoma, MM multiple myeloma, MRD minimal residual lesion, ORR objective remission rate, OS overall survival, PFS progression-free survival, RR relapsed/refractory, TTP time to progression